MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.910
-0.030
-1.55%
Closed 16:53 07/06 EDT
OPEN
1.980
PREV CLOSE
1.940
HIGH
1.990
LOW
1.900
VOLUME
582.92K
TURNOVER
--
52 WEEK HIGH
6.49
52 WEEK LOW
1.125
MARKET CAP
204.31M
P/E (TTM)
3.104
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LXRX stock price target is 4.700 with a high estimate of 9.00 and a low estimate of 2.100.

EPS

LXRX News

More
Should You Buy Lexicon Pharmaceuticals, Inc. (LXRX)?
Insider Monkey · 2d ago
Lexicon Pharmaceuticals Presents Clinical Data for Zynquista at ADA Scientific Sessions; Phase 3 CKD-3 Study Met Primary Endpoint; Phase 3 CKD-4 Study Did Not
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) on Saturday presented six posters for Zynquista (sotagliflozin) at the virtual 80th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type 2 diabetes
Benzinga · 06/14 12:16
Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions
GlobeNewswire · 06/13 16:01
Edited Transcript of LXRX earnings conference call or presentation 27-Apr-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/11 22:22
Top Biotech Stocks for Q3 2020
The biotechnology industry includes companies that develop drugs and diagnostic compounds for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Biotech
Investopedia · 06/09 18:09
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GlobeNewswire · 05/27 12:00
Lexicon Pharma Highlights Will Present Preclinical Efficacy Data On Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell
Benzinga · 05/13 22:01
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines
Lexicon Pharmaceuticals, Inc. (LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the Am
GlobeNewswire · 05/13 21:30

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About LXRX

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
More

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.